Aeglea BioTherapeutics: Enzyme Replacement Therapy

  • Home
  • Aeglea BioTherapeutics: Enzyme Replacement Therapy

Aeglea BioTherapeutics is in the process of developing an enzyme replacement therapy for patients with CBS Deficiency Homocystinuria.
For the most up-to-date news on their enzyme replacement, please visit their website: Click here

October 27, 2022

KOL Webinar on Classical Homocystinuria and Pegtarviliase

October 4, 2022

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory
Update for Homocystinuria Program

August, 29 2022

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

August, 4 2022

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates

6/24/2021
Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria

December 1, 2020
Aeglea BioTherapeutics Receives FDA Rare Pediatric Designation for ACN00177 for the Treatment of Homocystinuria

October 27-30, 2020
Development of a Novel Human Engineered Enzyme (ACN00177) for the Treatment of Homocystinuria Poster Presentation (Abstract)

October 26, 2020
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria

January 13, 2020

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

October 19, 2018
Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference

October, 2018

Improved Survival & Amelioration of Disease-Related Liver Pathology in a Mouse
Model of Homocystinuria with a Novel Homocysteine Degrading Enzyme (Aeglea Poster)

October 10, 2018

Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting

Positive Preclinical Efficacy Data on its AEB4104 Homocystinuria Therapeutic Program

July 30, 2018

Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule

Preclinical Efficacy Data of AEB4104 - a New Enzyme Approach - for the treatment of Homocystinuria

Pages

© 2016 Enigma Theme|Theme Developed By Weblizar Themes

Verified by ExactMetrics